MedTrace Logo

Reticular Pseudodrusen Progression Study

NCT02345317 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2015-01-26

No results posted yet for this study

Summary

Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in industrial countries. Reticular pseudodrusen (RPD) have been recognized as an additional phenotypic characteristic frequently observed in patients with AMD. Several studies have proven that the prevalence of RPD is associated with AMD as well as a high risk of disease progression to geographic atrophy, the late form of dry AMD. The pathogenesis of RPD is yet still incompletely understood. Retrospective studies have demonstrated that the RPD affected retinal area increases over time. Potential factors influencing progression of RPD have not been intensely studied and potentially predictive markers are yet unknown. The primary objective of this study is to characterize RPD progression in more detail and to identify predictive markers of RPD progression and development of AMD late stages.

Conditions

  • Age-related Macular Degeneration

Sponsors & Collaborators

  • University Hospital Muenster

    lead OTHER

Principal Investigators

  • Nicole Eter, Prof · Department of Ophthalmology, University Medical Center Muenster

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2017-07-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02345317 on ClinicalTrials.gov